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0929-6646/Copyright ª 2015, FormosaBackground/Purpose: Traditionally, guide bone regeneration (GBR) was a widely used method
for repairing bone lost from periodontal disease. There were some disadvantages associated
with the GBR method, such as the need for a stable barrier membrane and a new creative cav-
ity during the surgical process. To address these disadvantages, the purpose of this study was
to evaluate a novel microinjector developed for dental applications. The microinjector was de-
signed to carry bone graft substitutes to restore bone defects for bone regeneration in peri-
odontal diseases. The device would be used to replace the GBR method.
Methods: In this study, the injected force and ejected volume of substitutes (including air, wa-
ter, and ethanol) were defined by Hooke’s law (nZ 3). The optimal particle size of bone graft
substitutes was determined by measuring the recycle ratio of bone graft substitutes from the
microinjector (nZ 3). Furthermore, a novel agarose gel model was used to evaluate the feasi-
bility of the microinjector.
Results: The current study found that the injected force was less than 0.4 N for obtaining the
ejected volume of approximately 2 mL, and when the particle size of tricalcium phosphate
(TCP) was smaller than 0.5 mm, 80% TCP could be ejected from the microinjector. Further-
more, by using an agarose model to simulate the periodontal soft tissue, it was also found that
bone graft substitutes could be easily injected into the gel.ave no conflicts of interest relevant to this article.
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46 H.-C. Tsai et al.Conclusion: The results confirmed the feasibility of this novel microinjector for dental applica-
tions to carry bone graft substitutes for the restoration of bone defects of periodontal disease.
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reserved.Figure 1 (A) The schematic diagram of a double-tube
structure of a dental microinjector; (B) photograph of a
novel dental microinjector.Introduction
Although periodontal disease is an infectious disease of the
gingival tissue, changes in the bone are crucial because bone
destruction eventually leads to tooth loss. Periodontal dis-
ease results in different types of defects in the alveolar bone.
These defects are called bone defects. Losing supporting
bone around a tooth results in the movement and dislocation
of that tooth, and systemic health is adversely affected.1e4
Traditionally, guide bone regeneration (GBR) was a
widely used method for repairing bone lost from peri-
odontal disease; it was based on barrier membranes with
bone graft sealing off the cavity site of bone for patients
with periodontal disease.5 Although GBR has been used for
the treatment of periodontal disease for 10 years, the
method has some disadvantages, such as the need for a
stable barrier membrane and a new creative space during
the surgical process.6e8 In addition, most patients do not
like the wound cavity created by surgical processes. A
microinjector with bone substitutes, therefore, was
developed to replace the GBR surgical process for restoring
bone defects in periodontal disease.
Although microinjection technology in general was
widely used in orthopedic surgery, plastic surgery, and
dermatology,9e11 it has not yet been used in dentistry. In
this study, a new microinjector was developed to carry
bone graft substitutes to repair bone defects of periodontal
disease; the use of the microinjector in dentistry is a new
concept. The advantages of a small wound, low injective
force, and minimal patient discomfort with microinjector
use have been reported previously.12e14 In this study, the
novel microinjector for dental application was designed to
carry bone graft substitutes. Compared with the traditional
GBR method, the microinjector for dental application is
very convenient because the bone defects could be filled by
the substitutes carried by the microinjector via a one-step
injection. The bone substitute used for testing was syn-
thetic calcium phosphate bone substitutes with similar
chemical components and structure to normal bone.15,16
Previous studies have also shown that synthetic calcium
phosphate substitute is osteoconductive and can be resor-
bed by the host body.17 Synthetic substitutes are advanta-
geous for applying for oral tissue engineering because they
have uniform particles, and are biocompatible, cheap, and
have no ethics-related issues.18
In this study, synthetic tricalcium phosphate (TCP) was
used as the bone substitute carried by the microinjector.
The injected force and ejected volume of substitutes from
the microinjector were investigated; the optimal particle
size of TCP was also determined. Furthermore, the feasi-
bility of microinjector use was evaluated with an agarose
gel model to observe the distribution of bone substitutes
ejected from the microinjector.Materials and methods
Design of the microinjector for dental applications
The novel microinjector for dental applications was
designed according to the following steps. Commercially
available syringe needles, 18G and 23G, were used in the
design of the microinjector. The microinjector was a
double-tube structure, and an 18G needle was used as the
outer tube for filling with bone substitutes, and a peak-
polished 23G needle was used as the inner tube to propel
the bone substitutes out, as shown in Figure 1.Analyzing the correlation between injected force
and ejected volume by Hooke’s law
The correlation between injected forces and ejected vol-
umes of substitutes was evaluated by Hooke’s law, which is
Novel microinjector for dentistry 47stated mathematically as follows: F Z kDx.19 In this study,
F is the applied force (N), k is the spring constant of spring
steel [SAE 1095, 0.0322 (N/mm)], and Dx is the strain of
spring [i.e., Dx Z xextend  xorignal, (mm)]. The force F was
calculated by the strain of spring when exerting a force on
the inner tube of the microinjector. Thus, the correlated
injected forces with the ejected volumes of substitutes
including air, water, and ethanol, respectively, were
measured.Optimal particle size of bone substitutes measured
by recycling test
The optimal particle size of bone graft substitute, TCP, for
the novel microinjector was evaluated using a recycling
test. The particle sizes of bone graft substitutes from
commercial products of TCP (Ostecera, Hsinchu, Taiwan)
used for testing in this study are about 0.25e0.50 mm,
0.50e1.00 mm, 1.0e2.0 mm, and 2.0e3.0 mm in dimen-
sion, respectively. According to the clinical experiences of
dentists, the general sizes of the oral cavities in periodontal
disease range from 0.15 cm3 to 0.25 cm3, but only 0.2 g of
bone graft substitute is the maximum amount required to
fill these cavities. Thus, the outer tube of the microinjector
was filled with 0.2 g of bone graft substitutes with different
particle sizes, and then the inner tube was exerted by a
force to extrude the bone graft substitutes. The recycle
ratio was calculated by measuring the volume ratio of
ejected and filled bone graft substitute. The results are
shown as the ratio (%) (bone graft substitutesextruded over
bone graft substitutesfilled). A high recycle ratio represents
better efficiency. The optimal particle size of the bone
graft substitutes could therefore be determined.0 ml 2 ml 4 ml
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n.s.n.s.Feasibility of the microinjector evaluated by an
agarose gel model
When evaluating the feasibility of the microinjector, it is
important to observe whether the bone graft substance can
be extruded easily and evenly distributed in the bone de-
fects. For this purpose, a novel agarose gel model for
evaluation was developed. In this study, 1% agarose gel was
filled in a 1-mL Eppendorf tube to form a cone shape for
simulating periodontal soft-tissue and bone defects. Bone
graft substitutes with a 0.25-mm to 0.50-mm particle size
were carried by the novel microinjector and were then
injected 2e3 mm in depth, into the agarose gel. A camera
(Canon, EOS 400D, Tokyo, Japan) was used to capture the
distribution of bone graft substitutes. The injection without
bone graft substitutes was used as a control. Because
agarose is soft and translucent, it is easy to observe the
distribution of extruded bone graft substitutes from the
microinjector.Figure 2 The correlation between injected force (N) and
ejected volumes of air, water, or ethanol. Results represent
the means  standard deviations from three independent ex-
periments for each condition (nZ 3/condition). No significant
differences (n.s.) were denoted compared with significant
difference (*p < 0.05), determined using analysis of variance
followed by a post hoc procedure (Duncan’s test).Statistical analysis
All statistical analysis was performed using one-way anal-
ysis of variance followed by a post hoc procedure (Duncan’s
test) with p < 0.05 considered significant for all tests.Results
Correlation between injected forces and ejected
volumes
Figure 2 shows the correlation between the injected forces
and the injected syringe volumes by Hooke’s Law. It was
observed that when injected volumes of air, water, and
ethanol were 2 mL and 4 mL, the injected forces are,
respectively, 0.31 0.04 N, 0.33 0.07 N, and 0.34 0.03 N
and 0.62  0.06 N, 0.53  0.07 N, and 0.56  0.08 N. These
data indicate that injected forces have a linear correlation
with injected volumes, but not with the type of substitutes.
Recycle ratio and optimal particle size of bone graft
substitutes
In order to choose the optimal particle size of bone graft
substitutes, the recycle ratio of TCP was estimated by the
developed microinjector. Figure 3 shows the recycle ratio
of TCP of different particle sizes 0.25e0.5 mm, 0.5e1 mm,
1e2 mm, and 2e3 mm were 83.3  4.2%, 25.8  1.4%,
0.0  0.0%, and 0.0  0.0%, respectively. It appeared that
when particle size was larger than 1 mm, the recycle ratio
of TCP is zero, which indicated that the TCP powder could
not pass through the microinjector. When the particle size
of TCP is in the range of 0.5e1 mm, the recycle ratio is
lower than 30%. The acceptable recycle ratio should be
larger than 80%; the optimal particle size of tested bone
graft substitutes, therefore, is 0.25e0.5 mm.
Evaluation of the feasibility of the microinjector
with an agarose gel model
The feasibility of the microinjector was evaluated with an
agarose gel model to represent the soft-tissue and bone
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Figure 3 The recycle ratio of different particle sizes of tri-
calcium phosphate (TCP), ejected from the microinjector.
Results represent the means  standard deviations from three
independent experiments for each condition (n Z 3/condi-
tion). No significant differences (n.s.) were denoted compared
with significant difference (**p < 0.01), determined using
analysis of variance followed by a post hoc procedure (Dun-
can’s test).
Figure 4 An agarose gel model used for observing the dis-
tribution of ejected bone substitutes from a microinjector to
evaluate the feasibility of the microinjector. (A) The 1%
agarose gel formed cone was used to stimulate alveolar soft
tissue; (B) the morphology of agarose gel without microinjec-
tion; (C) agarose gel before microinjection and distribution of
bone graft substitutes after microinjection of bone graft sub-
stitutes, tricalcium phosphate (TCP), into the agarose gel.
48 H.-C. Tsai et al.defects. By using the developed microinjector, bone graft
substitutes TCP with a particle size of 0.25e0.5 mm was
found to be ejected and distributed in agarose gel as shown
in Figure 4. The agarose model demonstrated that bone
graft substitutes can be carried by a microinjector and
ejected into bone defects easily and suggested the feasi-
bility of the microinjector for dental applications. Figure 5
is a schematic diagram showing the application of a
microinjector to carry bone graft substitutes for injection
with only a small invasion wound and avoiding a flap
operation for the patients.
Discussion
In the current study, a novel dental microinjector was
designed to carry bone graft substitutes for restoring bone
defects for bone regeneration in periodontal diseases.
Synthetic TCP was used as the bone substitute for testing in
this study. Calcium phosphate has been widely used as a
bone graft substitute since 1920.15 It has been reported
that calcium phosphate could supply nutrition for cells and
then promote bone formation.20,21 Recently, GBR with bone
graft substitutes are applied to restore bone defects in
periodontal diseases.22 However, it is usually necessary to
create a new and large wound in the patients receiving
treatment with the GBR method.
The novel microinjector has double tubes and is easy to
handle (Figure 1A). The total length of the dental micro-
injector was only 4.8 cm, which is smaller than a com-
mercial clinical syringe (Figure 1B) and is easy to
manipulate. The correlation between the injected force
and ejected volume of substitutes was measured using
Hooke’s law. It appeared that, in the elastic range, the
ejected volumes of substitutes had no significant differ-
ences among air, water, and ethanol. It was also found that
the injected force is less than 0.4 N for obtaining theejected volume of about 2 mL (Figure 2). This suggests that
the device was easy to carry and saved effort. In this study,
the recycle ratio of the bone graft substitute, TCP, with
different particle sizes to estimate the optimal particle size
of the bone substitutes was measured. According to the
results of the recycle ratio, it was found that if the particle
size of TCP was smaller than 0.5 mm, 80% TCP could be
ejected (Figure 3). Previous studies reported the injection
Figure 5 The schematic diagram of the TAIDA injector injecting tricalcium phosphate (TCP) into alveolar tissue.
Novel microinjector for dentistry 49of calcium hydroxyapatite gel and hyaluronic acid gel for
the rejuvenation or treatment of infraorbital hollows and
dark circles.23,24 The materials used in these reports were
in gel state. For dental applications of the novel micro-
injector, the bone graft substitutes for injection were TCP
powder. Previous studies have shown that calcium phos-
phate powder has bioactivity and osteoconductivity.25e27
This suggests that a powdered bone graft substitute is
suitable for bone regeneration in periodontal disease.
Previous studies show that the stiffness of the artificial
human oral mucosa stroma (HOMS) based on agarose is
similar to human soft tissue; then, after transplantation, a
HOMS based on agarose to be an engineering gingival tissue
could profile the expression of cytokeratin of oral mucosa
and reconstruct the oral cavity.28,29 For these reasons, a
novel agarose gel model was developed by using 1% agarose
gel to mimic the soft-tissue and bone defects for measuring
the volume and distribution of ejected bone graft sub-
stitutes for evaluation of the feasibility of the micro-
injector. The density of 1% agarose gel is similar to the soft-
tissue and bone defects. The optical transparency of the
agarose gel also provides an excellent view of the distri-
bution of the bone graft substitutes. It was found that TCP
could be ejected into agarose gel effectively through the
microinjector (Figure 4). The feasibility of the dental
microinjector indicated that this method can replace the
traditional GBR method, which has the disadvantages of
requiring a suitable barrier membrane and a two-stage
surgical process.28,29 Compared to the traditional GBR
method, by using the novel microinjector, no barrier
membrane is necessary, only a one-step procedure is
necessary, and the injected wound is very small (Figure 4).
The feasibility of the microinjector was demonstrated by
the agarose gel model and suggests that it is worthy of
further clinical applications.
In this study, the novel developed dental microinjector
to carry bone graft substitutes for replacing the traditional
GBR method for bone regeneration in the periodontal field
was evaluated. It was demonstrated that the optimal size
of the bone graft substitutes is 0.25e0.5 mm, and anejected volume of the substitutes of about 2 mL only
require an injected force of about 4 N, which is indicative
of the ease of manipulation of the microinjector. The
feasibility of the microinjector was also proven by the novel
agarose gel model. It was also found that the agarose model
is a good model for mimicking the soft-tissue and bone
defects and helps investigate the distribution of the ejec-
ted bone graft substitutes. It has been shown that the
dental microinjector serves as a new device that can carry
bone graft substitutes when repairing the bone defects
from periodontal diseases. The manufacturing process
guarantees controllable, consistent, and reproducible
dental treatment quality. These findings are very encour-
aging and worthy of further clinical applications.Acknowledgments
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